The 2023 People's Finance Forum convened at the People's Daily headquarters on 29 December, where Synaura Biotech once again received honours! Centred on the theme ‘Advancing Chinese Modernisation through High-Quality Development’, the forum was attended by leaders from ministries including the Ministry of Natural Resources, Ministry of Ecology and Environment, Ministry of Transport, Ministry of Water Resources, and Ministry of Culture and Tourism. During this prestigious event, the recipients of the ‘People's Artisanal Technology Award’ were announced. Synaura Biotech was honoured for its pioneering indigenous Chinese HMO technology, exemplifying the perfect fusion of craftsmanship and technological innovation. Synaura Biotech's accolade not only signifies high recognition for its technological innovations but also marks a significant stride in advancing HMO industrialisation and achieving high-quality development within the dairy sector, thereby making a substantial contribution to China's modernisation drive. Synaura Biotech drives industrial upgrading through technological innovation, propelling China's domestic dairy industry to new heights!

Recently, the China Bio-Manufacturing Industry Development Conference, themed ‘Synthetic Biology: Boundless Vitality’, was held in Shijiazhuang, Hebei Province. The event unveiled the ‘2023 List of Rising Stars in Bio-Manufacturing’, aiming to establish a professional exchange and collaboration platform within China's bio-manufacturing sector and propel its vigorous development. The conference brought together academicians, experts, leading enterprises, and representatives from investment institutions for in-depth discussions, collectively striving to foster an open ecosystem featuring a virtuous cycle of ‘technology-industry-finance’. At this prestigious event, Synaura Biotech's inclusion on the list stood out as a highlight. This recognition not only signifies high praise for its R&D innovations in the food biomanufacturing sector but also fully affirms its contributions to advancing the industry's development. Synaura Biotech Honoured on the 2023 List of Rising Stars in the Biomanufacturing Sector He Yaqiong, Director-General of the Department of Consumer Goods Industry at the Ministry of Industry and Information Technology, stated that the biotechnology sector represents one of the most promising strategic emerging industries for the future. Advancements in biomanufacturing hold the potential to reshape industrial ecosystems and future development paradigms, constituting an essential requirement for advancing new industrialisation. The China Bio-Manufacturing Industry Development Conference, renowned for its professionalism and authority, is hailed as the ‘barometer’ of China's bio-economy sector. The companies featured on this list of emerging enterprises in bio-manufacturing not only represent the vanguard of China's innovation journey in bio-manufacturing, but their pioneering ventures also signal potential future trajectories for the industry. Five Key Advantages of Synaura HMO Synaura Biotech employs advanced microbial fermentation technology to produce HMO, meticulously refining its products. Through continuous process optimisation, the resulting HMO exhibits uniform particle size, high purity, and no residual acetic acid odour – perfectly embodying the fusion of craftsmanship and technological innovation. Extensive customer validation has demonstrated that Synaura Biotech's HMOs have gained widespread market recognition for their exceptional quality, ease of application, and adaptability to diverse production methods including dry and wet processes. Simultaneously, this accolade serves as both an incentive and a spur for the future—driving Synaura Biotech to deepen its innovative researchbio-active ingredients like human milk oligosaccharides, continuously enhance its scientific and production capabilities in the field of biosynthesis, and fulfil its mission of independent innovation. This endeavour will propel China towards becoming a flagship leader in the Fourth Industrial Revolution. The future is here, and China's era of independent innovation has arrived!

On 24 November 2023, Mengniu Future Star Children's Milk officially launched China's first HMO-enriched liquid formula for children. This new product specifically incorporates Synaura™ HMOs (human milk oligosaccharides) independently developed by SYNAURA Biotech. According to the brand, the product targets children aged three and above transitioning from infant formula to cow's milk. SYNAURA Biotech Empowers Clients to Expandthe HMO Liquid Milk Market Segment According to the brand, Mengniu Future Star is China's inaugural HMO-enriched liquid infant formula for children. With its specialised HMO formulation, the product aims to seize market initiative in this emerging segment by establishing itself as the pioneering offering. On 7 October, China's National Health Commission announced that 2′-FL (2′-fucosyllactose) and LNnT (lactose-N-neo-tetrasaccharide) within HMOs have been formally approved as food nutritional fortifiers. These may now be incorporatedinfant formula milk powder, modified milk powder (for children), and special medical infant foods. SYNAURA Biotech stands as the first Chinese manufacturer of HMOs to receive this initial round of approvals. According to the Scientific Consensus on Human Milk Oligosaccharides (HMOs), HMOs constitute the third most abundant solid component in breast milk and play a significant role in meeting the nutritional needs of infants and young children. Research indicates that HMOs help regulate the proportion of bifidobacteria in the infant gut, reduce the incidence of lower respiratory tract infections and otitis media, and decrease the use of antipyretic and antibiotic medications [1]. SYNAURA Biotech Advances Industrialisation of HMOs Publicly available data indicates that HMOs, touted as ‘maternal protective agents’, though abundant in human milk, are difficult to supplement via cow's or sheep's milk due to their low concentration in these sources and structural differences from human milk oligosaccharides[2]. Consequently, the industrialisation of HMOs holds significant importance for improving infant health and meeting nutritional requirements. Historically, HMO industrialisation technology has been firmly controlled by European and American giants, presenting a critical bottleneck for Chinese dairy enterprises pursuing precision nutrition research. Overcoming this technological barrier to achieve localised, industrial-scale HMO production has long been a shared aspiration and objective for all Chinese dairy companies. SYNAURA Biotech, as a pioneering domestic raw material enterprise in China, has forged ahead with unyielding determination and a trailblazing spirit. Through relentless endeavour, it has successfully launched China's first independently developed HMO raw material product, achieving multiple ‘firsts’ that have propelled its momentum to unstoppable heights. In January 2023, SYNAURA Biotech became the first Chinese HMO raw material enterprise to pass the safety assessment conducted by the Ministry of Agriculture and Rural Affairs; In June of the same year, the Scientific Consensus on Human Milk Oligosaccharides (HMOs) was formally published in the Chinese Journal of Food Science, marking SYNAURA Biotech as the first Chinese HMO raw material enterprise to participate in this authoritative release. That same month, it obtained US FDA self-GRAS market access approval. By October, SYNAURA Biotech's HMOs gained approval from the National Health Commission, making it the first and only domestic Chinese enterprise among the initial batch of approved companies. This time, Mengniu Future Star has pioneered the incorporation of HMOsliquid milk, translating scientific researchproduct innovation. This proactive positioning secures a first-mover advantage in market capture while further enhancing brand competitiveness. Throughout this process, SYNAURA Biotech's pivotal role cannot be overlooked; its advanced R&D innovations in HMOs laid the foundation for this formula upgrade. Moreover, the application of SYNAURA Biotech's HMOs in children's milk has broadened the scope of HMO usage in China, propelling industry development and accelerating consumer benefits by delivering superior, more nutritious products. We look forward to the launch of further HMO-enriched products, bringing premium nutritional health offerings to countless Chinese households. [1]中国食品科学技术学会,《母乳低聚糖（HMOs）的科学共识》,2023年7月,中国食品学报 [2]Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012 Sep;22(9):1147-62.

On 25 October, the 2023 Annual Meeting and Third Technical Symposium of the National Standardisation Innovation Base (Dairy Industry) (NSID) convened in Beijing. Synaura was honoured with the JinLi Innovation Project award from the National Standardisation Innovation Base (Dairy Industry), fully demonstrating the company's outstanding capabilities in R&D innovation and industrial transformation within the field of biosynthetic technology. This recognition signifies Synaura's significant contribution to advancing standardisation and high-quality development within China's dairy industry. Dairy Innovation: An Inevitable Trend The National Technology Standards Innovation Base (Dairy Industry) (hereinafter referred to as the Dairy Innovation Base) serves as a platform to advance standardisation and technological innovation within the dairy sector. To implement the National Standardisation Development Outline and leverage the role of innovation bases, the Dairy Innovation Base has collaborated with the National Technical Committee for Food Industry Standardisation (SAC/TC64), the National Technical Committee for Food Quality Control and Management Standardisation (SAC/TC313), the National Working Group for Food Nutrition and Health Management Standardisation (SAC/SWG25), and the National Food Fermentation Standardisation Centre. This initiative aims to showcase and promote advanced innovative technologies and standards within the industry, thereby enhancing the level of technological and standard innovation in the dairy sector and driving the high-quality development of China's dairy industry. Synaura Secures Further Accolade Synaura's project proposal, ‘Microbial Fermentation Method for Preparing 2'-Fucosyllactose (2'-FL) and Its Industrial Applications,’ has been honoured with the JinLi Innovation Project award. This recognition follows the project's outstanding innovation capabilities and industrial achievements, having successfully navigated three rounds of rigorous evaluation: formal review, expert correspondence assessment, and expert panel review (including defence). Ultimately, it distinguished itself among 73 competing proposals to claim this prestigious distinction. Synaura Biotech is a nationally leading bio-manufacturing enterprise possessing advanced synthetic biology technologies. The company specialises in developing synthetic biology methodologies and applying them to large-scale production. Presently, Synaura Biotech has established an extensive biological resource engineering library platform, accumulating substantial expertise in biosynthesis, intelligent design of high-performance cell factories, and scaled-up product manufacturing. Synaura Biotech remains committed to driving innovation and advancement in biotechnology, delivering premium products and services to global clients. Pioneering Innovation, Leading the Way Synaura's recent award of the JinLi Innovation Project Certificate from the National Technical Standards Innovation Base (Dairy Sector) represents not only the highest recognition of our company's outstanding achievements in HMO product R&D and industrial application, but also a commendation of our steadfast commitment to innovation, industrial transformation capabilities, and social responsibility. Synaura channels its scientific prowessconfidence, actively advancing its nutrition leadership strategy to spearhead industrial chain development and drive the commercialisation of research outcomes. Our vision is to become an industry leader, propelling China's biosynthetic sector onto the global stage and contributing Chinese wisdom and strength to the advancement of worldwide biosynthetic technology!

Synaura's 2'-FL (2'-fucosyllactose) received approval from the National Health Commission this October, making it among the first domestically produced HMOs to gain authorisation in China. Multiple media outlets have hailed it as ‘China's dark horse that has resolved the bottleneck caused by Western technology’. In fact, as early as 2022, Synaura had already begun expandingoverseas markets. This June, it conducted a self-GRAS scientific evaluation in accordance with the U.S. FDA's Generally Recognised as Safe (GRAS) guidelines and received expert approval. Synaura Biotech ExpandsInternational Markets Synaura Biotech has secured U.S. self-GRAS market access approval, formally entering the international market. Synaura's 2'-FL successfully obtained US FDA self-GRAS market access approval on 1 June 2023, marking a milestone achievement as the first instance of a Chinese enterprise securing global market access in the HMO sector through proprietary intellectual property. Concurrently, the company's independently developed 2'-FL (2'-fucosyllactose) has submitted safety certification applications to regulatory authorities across multiple countries worldwide. The attainment of self-GRAS safety certification signifies Synaura's HMOs have entered the international arena, establishing them as a globally recognised emblem of Chinese manufacturing. Awarded multiple titles as ‘China's Local Market Leader’ Synaura, as a homegrown emerging raw materials enterprise in China, has claimed multiple ‘firsts’ in the domestic market, emerging as a formidable new force with remarkable momentum and garnering significant attention for its capabilities. Its core product, HMO, has secured numerous top accolades, propelling its unstoppable rise. The Scientific Consensus on Human Milk Oligosaccharides (HMOs) was formally published in the Chinese Journal of Food Science, with Synaura becoming the first Chinese HMO raw material enterprise to participate in this authoritative release. As the leading domestic HMO enterprise in China, Synaura possesses formidable development potential while also bearing the significant responsibility and commitment to spearhead innovation as a local company. Synaura HMO Exceptional Performance Scientifically validated, Synaura Biotech's HMO products exhibit identical structural composition to human milk oligosaccharides extracted from Chinese mothers' breast milk. HMO (human milk oligosaccharides) delivers significant benefits across three key areas: maintaining gut health, enhancing the immune system, and boosting cognitive development. In maintaining gut health, HMOs can repair the intestinal barrier, improve the gut microbiota micro-ecology, and alleviate intestinal disorders; In enhancing the immune system, HMOs promote immune system maturation, resist pathogen invasion, and mitigate allergic reactions; In boosting cognitive abilities, HMOs have demonstrated remarkable efficacy in promoting brain development and enhancing learning and memory capacities. Clinical studies indicate that HMO supplementation increases bifidobacteria levels in infant gut flora, reduces the incidence of lower respiratory tract infections and otitis media, and decreases reliance on antipyretics and antibiotics. For adults, HMOs demonstrate efficacy in alleviating symptoms of irritable bowel syndrome and ulcerative colitis. Synaura's 2'-FL has achieved dual certification as self-GRAS in the U.S. and by China's National Health Commission, marking a groundbreaking milestone in HMO research and application. Moving forward, the company will continue to deepen innovative researchbioactive components such as human milk oligosaccharides, actively expanding the boundaries of scientific research categories while strategically positioning itself in other health sectors. This approach aims to achieve the organic integration of scientific research with industrialisation of outcomes. Synaura Biotech is committed to championing domestic innovation, driving the vigorous advancement of indigenous biosynthetic technologies, and propelling China to become a flagship leader in the Fourth Industrial Revolution.